Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Cebon

Showing results (51-60 of 67) with videos related to

Pageof 7
Sort By:
Lancet (London, England)|November 9, 1996
Thrombopoietic effects of pegylated recombinant human megakaryocyte growth and development factor (PEG-rHuMGDF) in patients with advanced cancerR L Basser, J E Rasko, K Clarke, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 17, 1998
Phase I and pharmacokinetic study of KRN8602 alone and with filgrastim in patients with advanced cancerK Clarke, R L Basser, D Maher, et al.
Cancer Chemotherapy and Pharmacology|January 1, 1997
Pharmacokinetics and pharmacodynamics of MX2 hydrochloride in patients with advanced malignant diseaseD J Morgan, J S Hill, K Clarke, et al.
Cancer Chemotherapy and Pharmacology|April 2, 1998
Effect of filgrastim on the pharmacokinetics of MX2 hydrochloride in patients with advanced malignant diseaseD J Morgan, J S Hill, K Clarke, et al.
Blood|May 1, 1997
Randomized, blinded, placebo-controlled phase I trial of pegylated recombinant human megakaryocyte growth and development factor with filgrastim after dose-intensive chemotherapy in patients with advanced cancerR L Basser, J E Rasko, K Clarke, et al.
British Journal of Cancer|April 16, 2002
Cancer testis antigens expression in mesothelioma: role of DNA methylation and bioimmunotherapeutic implicationsL Sigalotti, S Coral, M Altomonte, et al.
Chinese Medical Journal|January 5, 2002
Expression of the MAGE-1 gene in human hepatocellular carcinomasH Chen, S Cai, Y Wang, et al.
Blood|November 1, 1996
Administration of pegylated recombinant human megakaryocyte growth and development factor to humans stimulates the production of functional platelets that show no evidence of in vivo activationC J O'Malley, J E Rasko, R L Basser, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 20, 1998
Rapid hematopoietic recovery after multicycle high-dose chemotherapy: enhancement of filgrastim-induced progenitor-cell mobilization by recombinant human stem-cell factorR L Basser, L B To, C G Begley, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 7, 2000
Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanomaM R Middleton, J J Grob, N Aaronson, et al.
Pageof 7

Showing results (51-60 of 67) with videos related to

Sort By:
Pageof 7
Lancet (London, England)|November 9, 1996
Thrombopoietic effects of pegylated recombinant human megakaryocyte growth and development factor (PEG-rHuMGDF) in patients with advanced cancerR L Basser, J E Rasko, K Clarke, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 17, 1998
Phase I and pharmacokinetic study of KRN8602 alone and with filgrastim in patients with advanced cancerK Clarke, R L Basser, D Maher, et al.
Cancer Chemotherapy and Pharmacology|January 1, 1997
Pharmacokinetics and pharmacodynamics of MX2 hydrochloride in patients with advanced malignant diseaseD J Morgan, J S Hill, K Clarke, et al.
Cancer Chemotherapy and Pharmacology|April 2, 1998
Effect of filgrastim on the pharmacokinetics of MX2 hydrochloride in patients with advanced malignant diseaseD J Morgan, J S Hill, K Clarke, et al.
Blood|May 1, 1997
Randomized, blinded, placebo-controlled phase I trial of pegylated recombinant human megakaryocyte growth and development factor with filgrastim after dose-intensive chemotherapy in patients with advanced cancerR L Basser, J E Rasko, K Clarke, et al.
British Journal of Cancer|April 16, 2002
Cancer testis antigens expression in mesothelioma: role of DNA methylation and bioimmunotherapeutic implicationsL Sigalotti, S Coral, M Altomonte, et al.
Chinese Medical Journal|January 5, 2002
Expression of the MAGE-1 gene in human hepatocellular carcinomasH Chen, S Cai, Y Wang, et al.
Blood|November 1, 1996
Administration of pegylated recombinant human megakaryocyte growth and development factor to humans stimulates the production of functional platelets that show no evidence of in vivo activationC J O'Malley, J E Rasko, R L Basser, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 20, 1998
Rapid hematopoietic recovery after multicycle high-dose chemotherapy: enhancement of filgrastim-induced progenitor-cell mobilization by recombinant human stem-cell factorR L Basser, L B To, C G Begley, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 7, 2000
Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanomaM R Middleton, J J Grob, N Aaronson, et al.
Pageof 7